News in a nutshell

No conflict, but FDA's head drug official steps aside from an approval processlinkurl:Janet Woodcock,;http://www.fda.gov/AboutFDA/CentersOffices/ucm193984.htm director of the Center for Drug Evaluation and Research (CDER) at the US Food and Drug Administration (FDA), has recused herself from the approval process for two competing blood-thinning drugs that mimic the anticoagulant with a troubled recent past, heparin. The FDA linkurl:claimed;http://www.baltimoresun.com/entertainment/michael-jackso

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
No conflict, but FDA's head drug official steps aside from an approval process
linkurl:Janet Woodcock,;http://www.fda.gov/AboutFDA/CentersOffices/ucm193984.htm director of the Center for Drug Evaluation and Research (CDER) at the US Food and Drug Administration (FDA), has recused herself from the approval process for two competing blood-thinning drugs that mimic the anticoagulant with a troubled recent past, heparin. The FDA linkurl:claimed;http://www.baltimoresun.com/entertainment/michael-jackson/sc-dc-fda04-20100204,0,7396350.story that Woodcock did not have a conflict of interest regarding the approvals, though she enlisted the linkurl:help;http://content.nejm.org/cgi/content/abstract/358/23/2457 of scientists from one of the competing drug makers, Momenta Pharmaceuticals, to investigate tainted supplies of heparin from China in 2008. According to the FDA, she stepped aside voluntarily, and the US Department of Health and Human Services has halted an investigation into allegations of a conflict lodged by Amphastar Pharmaceuticals -- the firm that's competing with Momenta for approval of their heparin generic.
Woodcock
Image: FDA
Reviewers to NIH: Huh?
The US National Institutes of Health's Office of Extramural Research released more linkurl:instructions;http://nexus.od.nih.gov/nexus/nexus.aspx?ID=379&Month=02&Year=2010 for reviewers of NIH's reformatted grant proposals, but a lack of clarity on how to score the "Overall Impact" of proposals is leaving some reviewers scratching their heads. At issue is the relative emphasis reviewers are to put on the details of research proposals versus the general impact the work might have on its field, and how to quantify the latter. According to the linkurl:DrugMonkey blog,;http://scienceblogs.com/drugmonkey/2010/02/more_maddening_instruction_for_1.php?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Drugmonkey+(DrugMonkey) the Office of Extramural Research seems to be contradicting itself, telling reviewers that "Overall Impact" is distinct from core review criteria (significance, innovation, approach, etc.) that have always been considered while stating that the "Overall Impact" score should "take into account the individual review criteria and provide an overall evaluation." European drug agency charts course for future treatments
The European Union's version of the FDA -- the European Medicines Agency (EMEA) -- also made news recently, laying out its roadmap for the next five years. The agency's linkurl:draft five-year plan,;http://www.ema.europa.eu/htms/general/direct/roadmap/roadmapintro.htm which is available for public comment, outlines a move toward regulating emerging treatment strategies such as personalized medicine, nanotechnology, synthetic biology, and regenerative medicine. MS drug connected to dangerous brain inflammation
The FDA has found a link between deadly brain inflammation and multiple sclerosis drug Tysabri. The FDA confirmed on Friday that 31 patients receiving the drug had experienced progressive multifocal leukoencephalopathy (PML), a swelling of brain tissue that is usually fatal, since mid-2006. The drug was linkurl:pulled;http://www.the-scientist.com/blog/display/55285/ in 2005 over concerns about PML but reentered the market in July 2006. New labeling for Tysabri, which has been used by more than 65,000 people worldwide, states that no patients taking the drug for less than 12 months have been reported to suffer from PML, and that one in 1,000 people taking the drug for 2-3 years, are expected to experience PML. Plants make progesterone
Finally, last week, researchers reported that they've found the female sex hormone progesterone in a plant. Previously, scientists thought that progesterone could only be produced by animals, but chemists at the University of Illinois, Chicago, linkurl:found;http://pubs.acs.org/cen/news/88/i06/8806notw9.html the compound in the leaves of the common walnut tree. The finding pushes back the date of progesterone's arrival on the evolutionary scene and hints at a broader physiological role for the compound.
**__Related stories:__***linkurl:Conflicts brewing at the FDA;http://www.the-scientist.com/blog/display/55887/
[13th August 2009]*linkurl:MS drug sickens patient...again;http://www.the-scientist.com/blog/display/55285/
[16th December 2008]*linkurl:Clearing Estrogen's Bad Name;http://www.the-scientist.com/article/display/55138/
[November 2008]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
Image of a woman in a microbiology lab whose hair is caught on fire from a Bunsen burner.
April 1, 2025, Issue 1

Bunsen Burners and Bad Hair Days

Lab safety rules dictate that one must tie back long hair. Rosemarie Hansen learned the hard way when an open flame turned her locks into a lesson.

View this Issue
Faster Fluid Measurements for Formulation Development

Meet Honeybun and Breeze Through Viscometry in Formulation Development

Unchained Labs
Conceptual image of biochemical laboratory sample preparation showing glassware and chemical formulas in the foreground and a scientist holding a pipette in the background.

Taking the Guesswork Out of Quality Control Standards

sartorius logo
An illustration of PFAS bubbles in front of a blue sky with clouds.

PFAS: The Forever Chemicals

sartorius logo
Unlocking the Unattainable in Gene Construction

Unlocking the Unattainable in Gene Construction

dna-script-primarylogo-digital

Products

Atelerix

Atelerix signs exclusive agreement with MineBio to establish distribution channel for non-cryogenic cell preservation solutions in China

Green Cooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Thermo Fisher Logo
Singleron Avatar

Singleron Biotechnologies and Hamilton Bonaduz AG Announce the Launch of Tensor to Advance Single Cell Sequencing Automation

Zymo Research Logo

Zymo Research Launches Research Grant to Empower Mapping the RNome